Navigation Links
RiversEdge BioVentures LLC to Provide Advisory and Investment Services in Life Sciences
Date:9/10/2009

The formation of RiversEdge BioVentures LLC is announced today by Principal and Founder, David A. Dodd.

Beaufort, SC (Vocus) - The formation of RiversEdge BioVentures LLC is announced today by Principal and Founder, David A. Dodd.

Prior to forming RiversEdge BioVentures LLC, Mr. Dodd achieved a highly distinguished career, serving in executive positions in several major pharmaceutical and life sciences companies.

Recently, Mr. Dodd served as President, CEO and Chairman of BioReliance Corporation, as an equity partner with Avista Capital Partners in establishing that organization as a stand-alone company following its purchase from Invitrogen Corporation (now, Life Technology, Inc.).

In addition, Mr. Dodd served as the non-executive Chairman of Stem Cell Sciences Plc. (LSE:AIM STEM; ASX: STC), leading a strategic transformation and eventual sale of that company to Stem Cells Inc. in April, 2009. Mr. Dodd also served on the Board of Stheno Corporation, a private life sciences technology company.

From June 2000 to July 2006, Mr. Dodd served as President, CEO and Director of Serologicals Corporation (NASDAQ: SERO), until the sale of Serologicals to Millipore Corporation (NYSE: MIL) in July, 2006.

From August 1995 until June 2000, he served as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc., and as a member of the Management Board for the Pharmaceutical Sector for Solvay S.A. Mr. Dodd also served as Chairman of the Board of Unimed Pharmaceuticals, Inc., a subsidiary of Solvay Pharmaceuticals. Prior to joining Solvay, he served in a number of management and executive positions with major life science corporations, including Wyeth, Bristol-Myers Squibb, and Abbott Laboratories.

Mr. Dodd holds a Bachelor of Science and Master of Science from Georgia State University and completed the Harvard Business School Advanced Management Program.

Contacts:
Kathryn Gallagher
RiversEdge BioVentures LLC
843.576.9840

Scott Litherland
Parallax Communications Group
317.335.7898

# # #

Read the full story at http://www.prweb.com/releases/2009/09/prweb2857834.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
2. Newbridge Securities Corporation Forms BioVentures Division
3. Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex
4. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
5. CardioDynamics Provides 2007 Shareholder Meeting Update
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
8. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
9. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
10. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
11. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments is ... Nanoscience Analytical offers a broad range of contract analysis services for advanced ...
(Date:10/7/2017)...  The 2017 Nobel Prize in Chemistry recognizes ... Joachim Frank and Richard Henderson ... (cryo-EM) have helped to broaden the use ... The winners worked with systems manufactured by Thermo ... resolved, three-dimensional images of protein structures that lead ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October ... on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker ... is free and open to the public, but registration is required. , WHAT: ...
(Date:10/5/2017)... ... ... Understanding the microbiome, the millions of bacteria that live in our guts, ... Future, the newest exhibit on display at the University City Science Center’s Esther Klein ... lens of the gut microbiome. , Gut Love opens October 12, 2017, and ...
Breaking Biology Technology:
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):